Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01952574 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 483
- Enrollment target
NCT01952574 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 483 participants.
The verdict
NCT01952574, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 483 participants
- Enrollment target
Study Summary
A study to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days in participants with episodic migraine.
Interventions
- DRUG Placebo
- DRUG Erenumab
- DRUG Erenumab PFS
- DRUG Erenumab AI/Pen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 483 participants |
| Start Date | 2013-08-06 |
| Est. Completion | 2019-11-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01952574
The ClinicalTrials.gov registry entry for NCT01952574 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 483 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01952574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01952574 about?
NCT01952574 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention". A study to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days in participants with episodic migraine.
What is the current status of trial NCT01952574?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 483 participants. The study started on 2013-08-06. Estimated completion is 2019-11-12.
What interventions are being tested in trial NCT01952574?
The interventions under investigation include: Placebo (DRUG), Erenumab (DRUG), Erenumab PFS (DRUG), Erenumab AI/Pen (DRUG).
Who is sponsoring clinical trial NCT01952574?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.